While Tunisia is preparing to receive its first batch of Russian vaccines against the coronavirus, the efficiency and safety of Spoutnik V are questioned.
It was the European Agency for Medicines (EMA) which has verbalized its concern through the president of its board of directors, Christa Wirthumer-Hoche, which has advised against the member countries of the European Union to approve the use of the Russian vaccine before the end of its exam.
“We need documents that we can examine. We also do not have data on vaccinated people and side effects for the moment. This is the reason why I strongly advise against nationally emergency authorization, “she said on the Austrian channel Orf.
“We may have Spoutnik V on the market in the future when the appropriate data has been studied.”
Recall that a first quantity of anti-Cavid-19 vaccines, Spoutnik, will be received this Tuesday, according to what was announced by the Presidency of the Republic.
This quantity will allow vaccination of 15 thousand people.
